Latest / Decera Clinical Education Oncology Podcast
PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting
In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including:
LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment
Abstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.